# Synthesis and Pharmacological Investigation of 5-Substituted-3-methylsulfanyl-1*H*-pyrazole-4carboxylic Acid Ethyl Esters as New Analgesic and **Anti-inflammatory Agents**

Authors

P. D. Gokulan<sup>1</sup>, B. Jayakar<sup>1</sup>, V. Alagarsamy<sup>2</sup>, V. Raja Solomon<sup>3</sup>

Affiliations

<sup>1</sup> Department of Pharmaceutical Chemistry, Vinayaka Mission's College of Pharmacy, Sankari Main Road, Ariyanoor, Salem, India

Department of Pharmaceutical Chemistry, MNR College of Pharmacy, Gr. Hyderabad. India Medicinal & Process Chemistry Division, Central Drug Research Institute, Lucknow, India

Kev words

- pyrazole derivatives

analgesic

anti-inflammatory activity ulcerogenic behaviour

received 18.03.2012 accepted 02.07.2012

**Bibliography** 

DOI http://dx.doi.org/ 10.1055/s-0032-1321830 Published online: August 29, 2012 Arzneimittelforschung 2012; 62:457-462 © Georg Thieme Verlag KG Stuttgart · New York ISSN 0004-4172

Correspondence

P. D. Gokulan Department of Pharmaceutical Chemistry Vinayaka Mission's College of Pharmacy Sankari Main Road Ariyanoor Salem - 636 308 India Tel.: +91/427/247 7903 Fax: +91/427/247 7903 drvalagarsamy@gmail.com gokulakila@yahoo.co.in

Abstract

Purpose: To synthesize a new series of 5-substituted-3-methylsulfanyl-1H-pyrazole-4-carboxylic acid ethyl esters for their analgesic and anti-inflammatory activity.

Methods: The title compound synthesized by reacting the amino group of 5-amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester with acid anhydrides, acid chlorides and phenyl dithiocarbamates. The synthesized compounds were characterized by IR, <sup>1</sup>H-NMR and mass spectral data; the purity of the compounds was determined by elemental analysis. The title compounds were investigated for analgesic, antiinflammatory and ulcerogenic behaviour.

Results: The compound 5-benzoylamino-3methylsulfanyl-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester (4c) emerged as the most active compound and exhibiting imperative analgesic and anti-inflammatory activities. Interestingly the test compounds showed only mild potential when compared ulcerogenic to indomethacin.

**Conclusion:** The compound (4c) could serve as a lead molecule for further modification to obtain a clinically useful novel class of analgesic and anti-inflammatory agents.

# Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the choice treatment in various inflammatory diseases such as arthritis, rheumatisms and relieve body aches and pain of everyday life [1-4]. However, long-term use of the NSAIDs has been associated with gastrointestinal ulceration, bleeding and nephrotoxicity [1–4]. Therefore the discovery of new safer antiinflammatory drugs represents a challenging goal for such a research area. The currently available NSAIDs belong to different chemical classes [5]. The pyrazole and substituted pyrazole derivatives have occupied a prominent place in medicinal chemistry because of their significant therapeutic properties in clinical applications [5–7]. In particular, it has been reported for diverse range of pharmacological activities including antihistamin, anti-arrhythmic, antiulcer, leishmanicidal, HIV-RT inhibitor, anti-cancer, antimalarial, anti-microbial, and cytotoxicity [7-13]. In addition to this several pyrazole analogs were also reported to exhibit analgesic and anti-inflammatory activity [7, 14-16].

However, tetra substituted pyrazole derivatives were not been studied towards analgesic and anti-inflammatory activities. Therefore, it was thought worthwhile to explore analgesic and anti-inflammatory activity of tetra substituted pyrazole derivatives. Accordingly the present work is concerned with the synthesis of tetra substituted pyrazole derivatives with the objective of discovering novel and potent analgesic and anti-inflammatory agents that might be devoid of gastrointestinal side effects. The synthesized compounds were tested for their analgesic, anti-inflammatory and ulcerogenic index behaviour.

**Materials and Methods** 

### Chemistry

Melting points (mp) were taken in open capillaries on Thomas Hoover melting point apparatus (Thomas Hoover, Philadelphia, USA) and are uncorrected. The IR spectra were recorded in film or in potassium bromide disks on a Perkin-Elmer 398 spectrometer (Bio Engineering, Wald, Switzerland). The <sup>1</sup>H NMR spectra were recorded on a DPX-300 MHz Bruker FT-NMR spectrometer (Pacific Northwest, Richland, Washington, USA). The chemical shifts were reported as parts per

million ( $\delta$  ppm) tetramethylsilane (TMS) as an internal standard. Mass spectra were obtained on a JEOL-SX-102 instrument (maspec, Tokyo, Japan) using fast atom bombardment (FAB positive). Elemental analysis was performed on a Perkin-Elmer 2400 CHN analyzer and values were within the acceptable limits of the calculated values (±0.4%). Spectral data (IR, NMR and mass spectra) confirmed the structures of the synthesized compounds; the purity of these compounds was ascertained by microanalysis. The progress of the reaction was monitored on readymade silica gel plates (Merck Whitehouse Station, NJ, USA) using chloroform/methanol (9:1) as a solvent system. Iodine was used as a developing agent. All chemicals and reagents used in the synthesis were obtained from Aldrich (Sigma-Aldrich, Spruce St. St. Louis, MO 63103), Lancaster (Alfa Aesar, Johnson Matthey Company, Ward Hill, MA 01835, USA) or Spectrochem Pvt.Ltd (Mumbai, India) and were used without further purification.

#### Ethyl 2-cyano-3,3-bis(methylthio)acrylate (2)

To a solution of dimethylformamide (30 mL) and 1.13 g (0.01 mol) of ethyl cyanoacetate (1), and sodium hydroxide (0.8g, 0.02 mol) in a minimum amount of water at 0 °C, was added. The reaction mixtures were treated drop wise 0.6 mL of carbon disulphide for 1h at 0°C with continues stirring. This mixture was further stirred for 1h with 2. 52g (0.02 mol, 1.9 mL) of dimethyl sulphate, which was added drop wise at 10-15 °C. The stirring was continued for further 3h and the reaction mixture was poured into ice-water. The precipitated product was filtered and dried; the precipitated was recrystallized from ethanol. Yield 93%; m.p.65–66 °C; Rf 0.78 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 1710 (Ester C=O Str), 1245 (Ester C-O Str), 767 (CN deformation), 686 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.33–1.36 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.60 (s, 3H, SCH<sub>3</sub>), 2.75 (s, 3H, SCH<sub>3</sub>), 4.26–4.30 (q, 2H,  $CH_2CH_3$ ; MS (*m*/*z*) 217 (M<sup>+</sup>); Anal. Calcd for  $C_8H_{11}NO_2S_2$ : C, 44.22; H, 5.1; N, 6.45; Found: C, 44.25; H, 5.08, N, 6.43.

# 5-Amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (3)

A mixture of 2.17g (0.01 mol) of ethyl 2-cyano-3,3-bis(methylthio) acrylate (**2**) and 0.5g (0.01 mol) of (99%) hydrazine hydrate in 25 mL of ethanol was refluxed for 2 h. The reaction mixture was cooled and poured into ice-water and filtered. The precipitated product was filtered and washed with water and dried; the precipitated was recrystallized from ethanol water (75:25) mixture. Yield 81%; m. p. 140–142 °C; Rf 0.36 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3389–3332 (NH<sub>2</sub> Str), 1653 (Ester C=O Str), 1626 (C=N Str), 1287 (Ester C-O Str), 659 (C-S-C); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.36–1.39 (t, *J*=7.0Hz, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.48 (s, 3H, SCH<sub>3</sub>),4.28–4.32 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 6.13 (br s, 2H, NH<sub>2</sub>), 12.87 (br s, 1H, NH); MS (*m*/*z*) 202 (M<sup>+1</sup>); Anal. Calcd for C<sub>7</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>S: C, 41.78; H, 5.51; N, 20.88; Found C, 41.74; H, 5.48; N, 20.85.

#### 5-Amino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4carboxylic acid ethyl ester (4)

A mixture of 2.17g (0.01 mol) of ethyl 2-cyano-3,3-bis(methylthio) acrylate (**2**) and 1.08g (0.01 mol) of phenyl hydrazine in 30 mL ethanol was refluxed for 2 h. The remaining procedure was the same as for compound **3**. Yield 85%; m. p. 95–97°C; Rf 0.39 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3331–3314 (NH<sub>2</sub> Str), 1669 (Ester C=O Str), 1608 (C=N Str), 1277 (Ester C-O Str), 687 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.39–1.42 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.54 (s, 3H, SCH<sub>3</sub>), 4.32–4.36 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 5.37 (br

s, 2H, NH<sub>2</sub>), 7.49–7.56 (m, 5H, Ar-H); MS (m/z) 277 (M<sup>+</sup>); Anal. Calcd for C<sub>13</sub>H<sub>15</sub>O<sub>2</sub>S: C, 56.41; H, 5.37; N, 13.16; Found C, 56.38; H, 5.35; N, 13.14.

## 5-Acetylamino-3-methylsulfanyl-1*H*-pyrazole-4carboxylic acid ethyl ester (3a)

5-Amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**3**) (2.01 g, 0.01 mol) and acetic anhydride (0.05 mol) was placed in a round bottom flask and refluxed for 3 h. The reaction mixture was cooled and poured into ice-water and filtered. The precipitated product was filtered and washed with water and dried; the precipitated was recrystallized from ethanol water (75:25) mixture. Yield 80%; m. p. 150–152 °C; Rf 0.39 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3344 (Pyrazole NH Str), 3269 (Amide NH Str), 1710 (Ester C=O Str), 1670 (Amide C=O Str), 597 (C=N Str), 1292 (Ester C-O Str), 705 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.38–1.41 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.26 (s, 3H, NHCOCH<sub>3</sub>), 2.53 (s, 3H, SCH<sub>3</sub>), 4.32–4.36 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 9.67 (br s, 1H, NH), 11.86 (br s, 1H, NH); MS (*m*/*z*) 242 (M<sup>+</sup>); Anal. Calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>S: C, 44.43; H, 5.39; N, 17.27; Found C, 44.4; H, 5.36; N, 17.24.

### 5-Chloroacetylamino-3-methylsulfanyl-1*H*-pyrazole-4carboxylic acid ethyl ester (3b)

5-Amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**3**) (2.01 g, 0.01 mol) was dissolved in 0.02 mol of glacial acetic acid, to this chloroacetylchloride (1.12 g, 0.01 mol) was added and reaction mixture was refluxed for 1 h. The remaining procedure was the same as for compound **3a**.Yield 82% m. p. 115–117 °C; Rf 0.37 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3315 (Pyrazole NH Str), 3279 (Amide NH Str), 1690 (Ester C=O Str), 1664 (Amide C=O Str), 1585 (C=N Str), 1298 (Ester C-O Str), 781 (C-Cl Str); 686 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.38–1.40 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.27 (s, 3H, SCH<sub>3</sub>), 4.22 (s, 2H, ClCH<sub>2</sub> CONH), 4.34–4.39 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 9.68 (br s, 1H, NH) 10.66 (br s, 1H, NH).; MS (*m*/*z*) 278 (M+); Anal. Calcd for C<sub>9</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub>S: C, 38.92; H,4.36; N,15.13; Found C,38.89; H,4.33; N,15.11.

## 5-Benzoylamino-3-methylsulfanyl-1*H*-pyrazole-4carboxylic acid ethyl ester (3c)

5-Amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (3) (2.01 g, 0.01 mol) was dissolved in 5 mL of pyridine to this was added benzoyl chloride (0.013 mol) drop wise with stirring. After the completion of addition, the mixture was stirred for further 1 h and then the pyridine was removed by high vacuum rotavapor and the reaction mixture was dried to obtain the precipitated product. It was crystallized with chloroform-ethanol mixture. Yield 74%; m. p. 123-125°C; Rf 0.71 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3230 (Pyrazole NH Str), 3190 (Amide NH Str), 1680 (Ester C=O Str), 1602 (C=N Str), 1550 (Amide C=O Str), 1250 (Ester C-O Str), 660 (C-S-C); <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>): δ 1.38–1.41 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.53 (s, 3H, SCH<sub>3</sub>), 4.30–4.35 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 7.48–7.54 (m, 5H, Ar-H), 8.47 (br s, 1H, NH), 9.41 (br s, 1H, NH); MS (m/z) 306 (M<sup>+</sup>); Anal. Calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S: C, 55.07; H, 4.95; N, 13.76; Found C, 55.04; H, 4.93; N, 13.73.

#### 3-Methylsulfanyl-5-(3-phenyl-thioureido)-1H-pyrazole-4-carboxylic acid ethyl ester (3d)

A mixture of compound 5-amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester ( $\mathbf{3}$ ) (0.01 mol) and methyl-(*N*phenyl) dithiocarbamate (0.01 mol) was dissolved in ethanol and a pinch potassium carbonate was added and refluxed for 9 h. The remaining procedure was the same as for compound **3a**. Yield 81%; m. p. 232–233°C; Rf 0.39 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>):3431 (NH Str), 323 (Amide NH Str), 1713 (Ester C=O Str), 1668 (Amide C=O Str), 1608 (C=N Str), 1278 (Ester C-O Str), 688 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.30–1.33 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.51 (s, 3H, SCH<sub>3</sub>), 4.62–4.66 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 7.28–7.39 (m, 5H, Ar-H), 8.12 (br s, 1H, NH), 8.81 (br s, 1H, NH), 9.46 (br s, 1H, NH); MS (*m*/*z*) 336 (M<sup>+</sup>); Anal. Calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub>: C, 49.98; H, 4.79; N, 16.65; Found C, 49.95; H, 4.75; N, 16.63.

#### 3-Methylsulfanyl-5-(3-(4-methyl phenyl)-thioureido)-1H-pyrazole-4-carboxylic acid ethyl ester (3e)

A mixture of compound 5-amino-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**3**) (0.01 mol) and methyl-(*N*-(4-methyl phenyl)) dithiocarbamate (0.01 mol) was dissolved in ethanol and a pinch potassium carbonate was added and refluxed for 12 h. The remaining procedure was the same as for compound **3a**. Yield 77%; m. p. 143–145 °C; Rf 0.41 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3362 (NH Str), 3296 (Amide NH Str), 1716 (Ester C=O Str), 1685 (Amide C=O Str), 1639 (C=N Str), 1226 (Ester C-O Str), 632 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.32–1.34 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.34 (s, 3H, SCH<sub>3</sub>), 2.46 (s, 3H, CH<sub>3</sub>), 4.24–4.27 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 7.15–7.17 (d, 2H, Ar-H), 7.31–7.32 (d, 2H, Ar-H), 7.39 (br s, 1H, NH), 8.44 (br s, 1H, NH), 9.17 (br s, 1H, NH); MS (*m*/*z*) 350 (M+); Anal. Calcd for C<sub>15</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub>: C, 51.41; H, 5.18; N, 15.99; Found C, 51.37; H, 5.15; N, 15.96.

### 5-Acetylamino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (4a)

A mixture of 5-amino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4**) (2.77 g, 0.01 mol) and acetic anhydride (0.05 mol) was placed in a RB flask and refluxed for 3 h. The remaining procedure was the same as for compound **3a**. Yield 79%; m. p. 171–173°C; Rf 0.48 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3388 (Amide NH Str), 1758 (Ester C=O Str), 1734 (Amide C=O Str), 1599 (C=N Str), 1239 (Ester C=O Str), 688 (C-S-C Str); <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>):  $\delta$  1.40–1–43 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.03 (s, 3H, NHCOCH<sub>3</sub>) 2.61 (s, 3H, SCH<sub>3</sub>), 4.31–4.34 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 7.51–7.59 (m, 5H, Ar-H), 9.61(br s, 1H, CONH); MS (*m*/*z*) 320 (M<sup>+</sup>); Anal. Calcd for C<sub>15</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S: C, 56.41; H,5.37; N,13.16; Found C, 56.38; H,5.35; N13.14.

# 5-Chloroacetylamino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (4b)

A mixture of 5-amino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4**) (2.77 g, 0.01 mol) was dissolved in glacial acetic acid (0.02 mol), to this chloro acetylchloride (1.12 g, 0.01 mol) was added and the reaction mixture was refluxed for 1 h. The remaining procedure was the same as for compound **3a**. Yield 89%; m. p. 161–163 °C; Rf 0.45 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3 220 (Amide NH Str), 1 706 (Ester C=O Str), 1669 (Amide C=O Str), 1559 (C=N Str), 1234 (Ester C-O Str), 774 (C-Cl Str), 657 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.39–1.40 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.57 (s, 3H, SCH<sub>3</sub>), 4.04 (s, 2H, CH<sub>2</sub>ClCONH), 4.31–4.36 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 7.34–7.52 (m, 5H, Ar-*H*), 8.35 (br s, 1H, CON*H*); MS (*m*/*z*) 353 (M<sup>+</sup>); Anal. Calcd for C<sub>15</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub>S: C, 50.92; H,4.56; N,11.88; Found. C, 50.89; H,4.54; N,11.85;

# 5-Benzoylamino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (4c)

A mixture of 5-amino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4**) (2.77 g, 0.01 mol) was dissolved in 5 mL of pyridine to this was added benzoyl chloride (0.013 mol) drop wise with stirring. After the completion of addition, the mixture was stirred for further 1 h and then the pyridine was removed by suction and the reaction mixture was dried to obtain the precipitated product. It was crystallized with chloroform-ethanol mixture. Yield 79%; m. p. 152–155 °C; Rf 0.65 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3290.82 (Amide NH Str), 1713 (Ester C=O Str), 1701 (Amide C=O Str), 1589 (C=N Str), 1236 (Ester C-O Str), 692 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.22–1.25 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.53 (s, 3H, SCH<sub>3</sub>) 4.27–4.31 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 7.25–7.46 (m, 9H, Ar-H), 7.80 (br s, 1H, CONH); MS (*m*/*z*) 382(M+) Anal. Calcd for C<sub>20</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S: C,62.97; H,5.02; N,11.02; Found C,62.94; H,4.98; N,10.99.

### 3-Methylsulfanyl-1-phenyl-5-(3-phenyl-thioureido)-1*H*pyrazole-4-carboxylic acid ethyl ester (4d)

A mixture of compound 5-amino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4**) (0.01 mol) and methyl-(*N*-phenyl) dithiocarbamate (0.01 mol) was dissolved in ethanol and a pinch potassium carbonate was added and refluxed for 10 h. The remaining procedure was the same as for compound **3a**. Yield 78%; m. p. 188–190°C; Rf 0.45 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3342 (NH Str), 3273 (NH Str), 1700 (Ester C=O Str) 1671 (Amide C=O Str), 1598 (C=N Str) 1278 (Ester C-O Str), 633 (C-S-C Str); <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>):  $\delta$  1.26–1.29 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.59 (s, 3H, SCH<sub>3</sub>), 4.29–4.33 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 6.83 (br s, 1H, NH), 7.31–7.40 m, (5H, Ar-H), 7.51–7.62 (m, 5H, Ar-H), 8.02 (br s, 1H, NH); MS (*m*/*z*) 412 (M<sup>+</sup>); Anal. Calcd for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub>: C,58.23; H,4.89; N,13.58; Found. C,58.2; H,4.85; N,13.55.

# 3-Methylsulfanyl-1-phenyl-5-(3-(4-methyl phenyl)thioureido)-1*H*-pyrazole-4-carboxylic acid ethyl ester (4e)

A mixture of compound 5-amino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4**) (0.01 mol) and methyl-(*N*-(4-methyl phenyl)) dithiocarbamate (0.01 mol) was dissolved in 20 mL of ethanol and a pinch potassium carbonate was added and refluxed for 13 h. The remaining procedure was the same as for compound **2**. Yield 81%; m. p. 211–212°C; Rf 0.71 (CHCl<sub>3</sub>: CH<sub>3</sub>OH, 9: 1); IR (KBr, cm<sup>-1</sup>): 3283 (NH Str), 3149 (NH Str), 1693 (Ester C=O Str), 1593 (C=N Str), 1246 (Ester C-O Str), 1138 (Thioamide C=S Str), 680 (C-S-C Str); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  1.39–1.41 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 2.32 (s, 3H, CH<sub>3</sub>), 2.54(s, 3H, SCH<sub>3</sub>), 4.32–4.36 (q, 2H, CH<sub>2</sub>CH<sub>3</sub>), 4.64(br s, 1H, NH), 7.20–7.28 (m, 5H, Ar-H), 7.49–7.56 (m, 4H, Ar-H), 7.90 (br s, 1H, NH); MS (*m*/*z*) 427(M<sup>+</sup>); Anal. Calcd for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub>: C,59.13; H,5.2; N,13.13; Found C,59.11; H,5.18; N,13.1

# Pharmacology

#### 

The synthesized compounds were evaluated for analgesic, antiinflammatory and ulcerogenic index. The test compounds and the standard drugs were administered in the form of a suspension (using 1% carboxymethylcellulose as a vehicle) by oral route of administration for analgesic and anti-inflammatory. For ulcerogenicity studies the drug were administrated by intraperitoneally as suspension in 10% V/V Tween 80. Each group consisted of six animals. The animals were procured from the Tetrex Biological Center, Madurai, India, and were maintained in colony cages at  $25\pm2$ °C, relative humidity 45–55%, under a 12h light and dark cycle; they were fed standard animal feed. All the animals were acclimatized for a week before use. The Institutional Animal Ethics committee has approved the protocol adopted for the experimentation of animals.

#### **Analgesic activity**

Test for analgesic activity was performed by tail-flick technique using Wistar albino mice (25–35g) of either sex selected by a random sampling technique [17–19]. The test compounds and pentazocine at a dose level of 5 mg kg<sup>-1</sup> was administered orally. The reaction time was recorded at 30 min and 1, 2 and 3 h after the treatment, and the cut-off time was 10s. The percentage analgesic activity (**• Table 1**) (PAA) was calculated by the following formula,

$$PAA = \left[\frac{T_2 - T_1}{10 - T_1}\right] \times 100$$

where  $T_1$  is the reaction time (s) before treatment, and  $T_2$  is the reaction time (s) after treatment.

#### Anti-inflammatory activity

Anti-inflammatory activity was evaluated by carrageenaninduced paw oedema test in rats [20]. The test compounds and Diclofenac sodium at a dose level of 5 mg kg<sup>-1</sup> was administered. The paw volumes were measured using the mercury displacement technique with the help of a plethysmograph immediately before and 1, 2 and 3 h after carrageenan injection. The percentage inhibition of paw oedema was calculated using (**• Table 2**) the following formula

Percent inhibition I = 100[1 - (a - x)/(b - y)]

Where x is the mean paw volume of rats before the administration of carrageenan and test compounds or reference compound (test group), a is the mean paw volume of rats after the administration of carrageenan in the test group (drug treated), b is the mean paw volume of rats after the administration of carrageenan in the control group and y is the mean paw volume of rats before the administration of carrageenan in the control group.

#### **Evaluation of ulcerogenicity index**

Fia. 1

4a-e.

Ulceration in rats was induced as described by reported protocol [21]. Albino rats of the Wistar strain weighing 150–200g of either sex were divided into various groups each of 6 animals. The control groups of animals were administered only 10% V/V Tween 80 suspension intraperitoneally. One group were administered with indomethacin intraperitoneally at a dose of 5 mg kg<sup>-1</sup> once daily for 3 days. The remaining group of animals was administered with test compounds intraperitoneally at a dose of 5 mg kg<sup>-1</sup>. On the fourth day, pylorus was ligated as per the method of Shay et al. [22]. Animals were fasted for 36 h before the pylorus ligation procedure. 4h after the ligation, animals were sacrificed. The stomach was removed and opened along with

Synthesis of pyrazole derivatives 3a-e and



10-15 °C, 3 h; (c) R-NH-NH<sub>2</sub>, ethanol reflux; (d) For compounds **3a** and **4a**  $(CH_3CO)_2O$  reflux; For compounds **3b** and **4b**; gla CH<sub>3</sub>COOH, Cl-CH<sub>2</sub>COCl reflux; For compounds **3c** and **4c** pyridine, benzoyl chloride reflux; For compounds **3d**, **3e**, **4d** and **4e** RCSNHR  $\Box$  K<sub>2</sub>CO<sub>3</sub>, ethanol reflux.

Compound	Dose (mg/kg)	Percent analgesic activity				Table 1 Analgesic activity of syn-	
		30 min	1 h	2h	3 h	thesized compounds ( <b>3a–e</b> and	
3a	5	23.61±0.65 <sup>d</sup>	38.00±0.60 <sup>c</sup>	57.24±0.21 <sup>c</sup>	16.07±0.01 <sup>c</sup>	<b>4a–e</b> ) by tail-flick technique.	
3b	5	$20.24 \pm 0.66^{e}$	31.55±1.01 <sup>c</sup>	47.62±0.58 <sup>c</sup>	13.39±0.80 <sup>c</sup>		
3c	5	$33.00 \pm 0.80^{\circ}$	39.32±0.99°	58.43 ± 0.97 <sup>c</sup>	$22.52 \pm 0.78^{d}$		
3d	5	$14.88 \pm 0.50^{e}$	27.67±0.50°	38.10±0.68 <sup>c</sup>	12.80±0.79 <sup>d</sup>		
3e	5	13.89±1.34 <sup>c</sup>	28.77±0.91 <sup>d</sup>	39.25±0.73 <sup>c</sup>	12.33±0.71 <sup>d</sup>		
4a	5	30.62±1.11 <sup>d</sup>	57.61±1.26 <sup>c</sup>	67.00±1.12 <sup>c</sup>	28.84±1.11 <sup>d</sup>		
4b	5	$27.68 \pm 0.94^{d}$	46.73±0.53 <sup>c</sup>	63.99±0.87 <sup>c</sup>	$21.13 \pm 0.60^{d}$		
4c	5	47.62±0.87 <sup>c</sup>	69.35±1.10 <sup>c</sup>	77.68±1.23 <sup>c</sup>	38.99±0.71°		
4d	5	$20.24 \pm 1.12^{e}$	36.31±0.65 <sup>c</sup>	$50.00 \pm 0.64^{\circ}$	17.56±1.26 <sup>c</sup>		
4e	5	23.31±0.96 <sup>e</sup>	42.16±1.16 <sup>c</sup>	58.93 ± 1.23 <sup>c</sup>	18.75±1.18		
Pentazocine	5	39.25±0.79°	66.47±0.73 <sup>c</sup>	77.25±0.43 <sup>c</sup>	65.09±0.71 <sup>c</sup>		
Control	-	$1.46 \pm 0.69$	$2.27 \pm 0.97$	3.02±0.51	$2.09 \pm 0.67$		

Each value represents the mean ± SD (n=6). Significant difference relative to control at same time points and comparison were measured:  ${}^{c}p$  < 0.001,  ${}^{d}p$  < 0.01,  ${}^{e}p$  < 0.05,

Table	2	Anti-inflammatory activity of synthesized compounds (3a-e and
4a–e)	) de	termined by Carrageenan induced paw oedema test in rats.

Compound	und Dose Percent P			Protection		
	(mg/kg)	1 h	2h	3h		
3a	5	28.57±1.1 <sup>c</sup>	$54.07 \pm 0.6^{\circ}$	$37.65 \pm 0.6^{\circ}$		
3b	5	21.77±0.8 <sup>c</sup>	$48.82 \pm 0.7^{\circ}$	$36.45 \pm 0.5^{\circ}$		
3c	5	$31.98 \pm 1.0^{\circ}$	$56.69 \pm 0.4^{\circ}$	$41.58 \pm 0.9^{\circ}$		
3d	5	21.77±0.8 <sup>c</sup>	$39.63 \pm 0.9^{\circ}$	$29.26 \pm 0.5^{\circ}$		
3e	5	25.17±1.6°	$44.88 \pm 0.5^{\circ}$	$30.46 \pm 0.6^{\circ}$		
4a	5	31.98±0.5°	56.69±0.3 <sup>c</sup>	$40.05 \pm 0.4^{\circ}$		
4b	5	25.17±0.7 <sup>d</sup>	52.75±0.5°	37.35±0.6 <sup>c</sup>		
4c	5	38.78±0.9°	$58.00 \pm 0.7^{\circ}$	$45.18 \pm 0.6^{\circ}$		
4d	5	21.77±0.3 <sup>c</sup>	42.26±0.9 <sup>c</sup>	35.25±0.3 <sup>c</sup>		
4e	5	21.77±0.8 <sup>c</sup>	46.19±0.6 <sup>c</sup>	37.65±0.9°		
Diclofenac sodium	5	62.58±0.2 <sup>c</sup>	73.75±0.4 <sup>c</sup>	$70.02 \pm 0.4^{\circ}$		
Control	-	$1.17 \pm 0.08$	$1.95 \pm 0.05$	$2.07 \pm 0.08$		
			10 110	1		

Each value represents the mean  $\pm$  SD (n = 6). Significant difference relative to control at same time points and comparison were measured:  $^{c}p$ <0.001,  $^{d}p$ <0.01,  $^{e}p$ <0.05,

the greater curvature. Ulcer index was determined by the method of Ganguly and Bhatnagar [23] and is recorded in **• Table 3**.

#### Statistical analysis

Statistical analysis of the biological activity of the synthesized compounds on animals was evaluated using a one-way analysis of variance (ANOVA). In all cases, post-hoc comparisons of the means of individual groups were performed using Tukey's test. A significance level of p < 0.05 denoted significance in all cases. All values are expressed as mean  $\pm$  SD (standard deviations). For statistical analysis we have used GraphPad Prism version 3.0. (GraphPad Software, Inc. San Diego, CA 92130 USA).

## **Results and Discussion**

▼

# Chemistry

The target compounds were synthesized according to steps outlined in **• Fig. 1**. The precursor of ethyl 2-cyano-3,3-bis(methylthio)acrylate (2) was easily synthesized by treatment of ethyl cyanoacetate (1) with carbon disulphide and sodium hydroxide in DMF to give sodium dithiocarbamate, which was methylated with dimethyl sulphate to afford the dithiocarbamic acid methyl ester (2). The compound (2) reacted with hydrazine and substituted hydrazine that gives 5-amino-3-methylsulfanyl-

1-substituted-1*H*-pyrazole-4-carboxylic acid ethyl ester (**3** and **4**) by 1,3-dipolar cyclo addition. The desired pyrazole derivatives (**3a–e** and **4a–e**) were obtained by the reaction of 5-amino-3-methylsulfanyl-1-substituted-1*H*-pyrazole-4-carboxylicacid ethyl ester with different reagents and conditions (**• Fig. 1**). The synthesized compounds were characterized by IR, <sup>1</sup>H-NMR, and mass spectral data. Elemental analysis satisfactorily confirmed elemental composition and purity of the synthesized compounds.

# Pharmacology

Test for analgesic activity was performed by tail-flick technique using Wistar albino mice [17-19]. The results of analgesic testing indicate that the test compounds exhibited moderate analgesic activity after 30 min of reaction time and an increase in activity after 1 h which reached a peak level after 2 h. Decline in activity was observed after 3h (**o Table 1**). According to the structure-activity relationship (SAR) studies, all the compounds have shown moderate analgesic activity when compared with reference drug pentazocine. Further results indicated that different substituents on the 5<sup>th</sup> position and N-1 pyrazole ring, exerted varied biological activity. Among the various amide (acetamide (**3a**), chloroacetamide (**3b**) and benzoyl amide (**3c**)) substitution on the 5<sup>th</sup> position, benzoyl amide substituted group (3c) showed significant activity. Compounds having 1-methyl-3-phenylthiourea (3d) and 1-methyl-3-p-tolylthiourea substitution (3e) on the 5<sup>th</sup> position of pyrazole ring system leads to abolish the analgesic activity. The phenyl substitution on N-1 pyrazole ring system led to significant increases in analgesic activity when compared to unsubstituted compounds. Among the series, 5-benzoylamino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (4c) is found to equipotent with the reference drug pentazocine (**•** Table 1).

Anti-inflammatory activity was evaluated by carrageenan induced paw oedema test in rats [20]. The anti-inflammatory activity data (• **Table 2**) indicated that all the test compounds protected rats from carrageenan-induced inflammation moderately after 30 min of reaction time with increased activity after 1 h that reached a peak level after 2 h. Decline in activity was observed after 3 h. The SAR studies indicated that different substituents on the 5<sup>th</sup> position and *N*-1 pyrazole ring, exerted varied protection effect from carrageenan-induced inflammation. The compound 5-benzoylamino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4c**) showed moderate anti-inflammatory activity when compared to the reference standard diclofenac sodium.

#### Table 3 Evaluation of ulcerogenic behavior.

Compound	Dose (mg/Kg)	Volume of gastric juice (mL/4h)	рН	Total acid out put (mEq/L)	Free acid (mEq/L)	Ulcer index
3c	5	4.34±0.2 <sup>a</sup>	2.15±0.3ª	29.54±0.3ª	11.76±0.5ª	1.84±0.5 <sup>a</sup>
4c	5	4.53±0.4ª	$2.13 \pm 0.2^{a}$	29.65±0.3ª	$11.78 \pm 0.5^{a}$	$1.68 \pm 0.4^{a}$
Indomethacin	5	10.32±0.4	$2.04 \pm 0.3$	60.33±0.5	$24.90 \pm 0.4$	$3.79 \pm 0.3$
Control	-	2.12±0.3	$3.84 \pm 0.5$	13.32±0.4	$5.85 \pm 0.2$	$0.06 \pm 0.01$

Each value represents the mean ± SD (n = 6). Significant difference relative to control at same time points and comparison were measured: cp < 0.001, dp < 0.01, ep < 0.05

Two selected compounds (**3c** and **4c**) of the series were evaluated for their ulcerogenic behaviour (**Table 3**). The ulcer index of the test compounds showed negligible ulcer index, when compared to reference standard indomethacin. The indomethacin induced ulcer model animals had ulcers and hemorrhagic streaks, where as in animals treated with the pyrazole derivatives compounds of (**3c** and **4c**) at 5 mg/kg dose level, there was a significant reduction in ulcer index. Furthermore the pyrazole derivatives (**3c** and **4c**) significantly reduces the total volume of the gastric juice, free and total acidity of gastric secretion and also has higher activity against gastric ulcers in rats when it was compared with indomethacin.

#### Conclusion

.

In the present study, synthesis of a new series of 5-substituted-3-methylsulfanyl-1*H*-pyrazole-4-carboxylic acid ethyl esters (**3a-e** and **4a-e**) has been described. The results of the analgesic and anti-inflammatory activities of the 5-substituted-3-methylsulfanyl-1*H*(substituted)-pyrazole-4-carboxylic acid ethyl esters series showed that moderate enhancement of activity. The compound 5-benzoylamino-3-methylsulfanyl-1-phenyl-1*H*-pyrazole-4-carboxylic acid ethyl ester (**4c**) emerged as the most active compound. Hence this series could be developed as a novel class of analgesic and anti-inflammatory agents. Further structural modification is planned to obtain compounds with increased analgesic and anti-inflammatory activities with minimal ulcerogenic behaviour.

#### **Acknowledgements**

▼

The authors thank the Head of RSIC, Indian Institute of Technology, Chennai for the mass spectral data and the head, sophisticated analytical instrument facilities, Central Drug Research Institute, Lucknow for NMR spectral data.

# Conflict of Interest Statement

V

The authors report no conflicts of interest to declare in connection with the contents of this manuscript.

References

- 1 Van Ryn J, Botting RM. New insights into the mode of action of antiinflammatory drugs. Inflamm Res 1995; 44: 1–10
- 2 Van Ryn J, Trummlitz G, Pairet M. COX-2 selectivity and inflammatory processes. Curr Med Chem 2000; 7: 1145–1161
- 3 Van Ryn J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology 1971; 231: 232–235
- 4 Beuck M. Nonsteroidal antiinflammatory drugs: A new generation of cyclooxygenase inhibitors. Angew Chem Int Ed 1999; 38: 631–633

5 Juby PF. In: Antiinflammatory Agents. Scerrer RA, Whitehouse MW. (Eds.), vol. I:Academic Press, New York: 1984; 91–127

- 6 Daidone G, Plescia S, Raffa D et al. Researches on antiinflammatory agents. Studies on some new 3-(pyrazol-5-yl)-1,2,3-benzotriazin-4(3H)-ones and -quinazolin-4(3H)-ones. Farmaco 1990; 45: 391–398
- 7 *Menozzi G, Mosti L, Bruno O et al.* Synthesis and biological evaluation of [alpha-(1,5-disubstituted 1H-pyrazol-4-yl)benzyl]azoles, analogues of bifonazole. Farmaco 1999; 54: 416–422
- 8 Naito H, Ohsuki S, Sugimori M et al. Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. Optimization of the phenylpiperazine moiety of 1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3phenylpiperazinyl-1-trans-propenes. Chem Pharm Bull (Tokyo) 2002; 50: 453-462
- 9 Park HJ, Lee K, Park SJ et al. Identification of antitumor activity of pyrazole oxime ethers. Bioorg Med Chem Lett 2005; 15: 3307–3312
- 10 Smith RA, Fathi Z, Brown SE et al. Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. Bioorg Med Chem Lett 2007; 17: 673–678
- 11 *Jorand-Lebrun C, Brondyk B, Lin J et al.* Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists. Bioorg Med Chem Lett 2007; 17: 2080–2085
- 12 Sakya SM, Hou X, Minich ML et al. 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile. Bioorg Med Chem Lett 2007; 17: 1067–1072
- 13 Diana P, Carbone A, Barraja P et al. 3,5-bis(3'-indolyl)pyrazoles, analogues of marine alkaloid nortopsentin: synthesis and antitumor properties. Bioorg Med Chem Lett 2007; 17: 6134–6137
- 14 Farag AM, Mayhoub AS, Barakat SE et al. Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity. Bioorg Med Chem 2008; 16: 4569–4578
- 15 Penning TD, Talley JJ, Bertenshaw SR et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347–1365
- 16 *Srivastava BK*, *Soni R*, *Patel JZ et al*. Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. Bioorg Med Chem Lett 2009; 19: 2546–2550
- 17 Amour RE, Smith DL. A method for determinating loss of pain sensation. J Pharm Exp Therap 1941; 72: 74–78
- 18 Kulkarni SK. Heat and other physiological stress-induced analgesia: Catecholamine mediated and naloxone reversible response. Life Sciences 1980; 27: 185–188
- 19 Eaton M. Common animal models for spasticity and pain. J Rehabil Res Dev 2003; 40: 41-54
- 20 Winter CA, Risely EA, Nuss GW. Carregeenin induced oedema in hind paw of the rat as assay for Antiinflammatory drugs. Exp Biol Med 1962; 111: 544–547
- 21 *Goyal RK, Chakrabarti A, Sanyal AK.* The effect of biological variables on the anti-ulcerogenic effect of vegetable plantain banana. Planta medica 1985; 29: 85–88
- 22 Shay M, Komarov SA, Fels D et al. A simple method for the uniform production of gastric ulceration in the rats. Gastroenterol 1945; 5: 43–61
- 23 Ganguly AK, Bhatnagar OP. Effect of bilateral adrenalectomy on production of restraint ulcers in the stomach of albino rats. Can J Physilo Pharmacol 1973; 51: 748–750